==== Reference: Usmani SS, Bedi G, Samuel JS, Singh S, Kalra S, Kumar P, et al. (2017) THPdb: Database of FDA-approved peptide and protein therapeutics. PLoS ONE 12(7) e0181748.====

Detailed description page of THPdb


Details of Th1022 which contains 32 entries.


Entry 1
(1) Primary information
ID1148
ThPP IDTh1022
Therapeutic Peptide/Protein NameAntihemophilic Factor
SequenceATRRYYLGAVELSWDYMQSDLGELPVDARFPPRVPKSFPFNTSVVYKKTL view full sequnce in fasta
Functional ClassificationIa
Molecular Weight264725.5
Chemical FormulaC11794H18314N3220O3553S83
Isoelectric Point6.97
Hydrophobicity-0.533
Melting Point (℃)N.A.
Half Life8.4-19.3 hours
DescriptionHuman recombinant antihemophilic factor or Factor VIII of 2332 residues(glycosylated) is produced by CHO cells.
Indication/DiseaseFor the treatment of hemophilia A, von Willebrand disease and Factor XIII deficiency.
PharmacodynamicsAntihemophilic Factor binds factor IXa along with calcium and phospholipid, this complex converts factor X to factor Xa to facilitate clotting cascade.
Mechanism of ActionAntihemophilic factor is a protein found in normal plasma which is necessary for clot formation. The administration of AHF provides an increase in plasma levels of AHF and can temporarily correct the coagulation defect of patients with hemophilia A.
ToxicityN.A.
MetabolismN.A.
AbsorptionN.A.
Volume of DistributionN.A.
Clearance4.1 mL/h/kg [Previously treated pediatric patients]
CategoriesCoagulants and Thrombotic agents
Patents NumberCA2124690
Date of Issue11/09/07
Date of Expiry01/10/13
Drug InteractionN.A.
TargetCoagulation factor X,Coagulation factor IX,von Willebrand factor,Phytanoyl-CoA dioxygenase, peroxisomal,Asialoglycoprotein receptor 2,78 kDa glucose-regulated protein,Calreticulin,Calnexin,Protein ERGIC-53,Prolow-density lipoprotein receptor-related protein 1,Multiple coagulation factor deficiency protein 2
Information of corresponding available drug in the market
Brand NameAdvate
CompanyN.A.
Brand DiscriptionAdvate contains antihemophilic factor, a naturally occurring protein in the blood that helps blood to clot. Advate works by temporarily raising levels of factor VIII in the blood to aid in clotting.
Prescribed forADVATE is a medicine used to replace clotting factor that is missing in people with hemophilia A. It is used to prevent and control bleeding in adults and children (0-16 years) with hemophilia A.
Chemical NameN.A.
FormulationN.A.
Physcial AppearancePowder form
Route of AdministrationIntravenous Injection
Recommended DosageDose (IU) = body weight (kg) _ Desired Factor VIII Rise (IU/dL or % of normal) _ 0.5 (IU/kg per IU/dL). So example, assuming assuming patient's baseline Factor VIII level is < 1% of normal = A dose of 1750 IU ADVATE administered to a 70 kg patient should be expected to result in a peak post-infusion Factor VIII increase of 1750 IU × {[2 IU/dL]/[IU/kg]}/[70 kg] = 50 IU/dL (50% of normal).
ContraindicationPatients who have life-threatening hypersensitivity reactions, including anaphylaxis, to mouse or hamster protein or other constituents of the product.
Side EffectsChest pain; easy bruising, increased bleeding episodes; or bleeding from a wound or where the medicine was injected.
Useful Linkhttp://www.advate.com/assets/pdf/advate_iri_pi.pdf
PubMed ID23803235, 23105376, 8328652, 2341766, 4708094, 2831669, 27445511, 25136251, 6197726
3-D StructureTh1022 (View) or (Download)


Entry 2
(2) Primary information
ID1149
ThPP IDTh1022
Therapeutic Peptide/Protein NameAntihemophilic Factor
SequenceATRRYYLGAVELSWDYMQSDLGELPVDARFPPRVPKSFPFNTSVVYKKTL view full sequnce in fasta
Functional ClassificationIa
Molecular Weight264725.5
Chemical FormulaC11794H18314N3220O3553S83
Isoelectric Point6.97
Hydrophobicity-0.533
Melting Point (℃)N.A.
Half Life8.4-19.3 hours
DescriptionHuman recombinant antihemophilic factor or Factor VIII of 2332 residues(glycosylated) is produced by CHO cells.
Indication/DiseaseFor the treatment of hemophilia A, von Willebrand disease and Factor XIII deficiency.
PharmacodynamicsAntihemophilic Factor binds factor IXa along with calcium and phospholipid, this complex converts factor X to factor Xa to facilitate clotting cascade.
Mechanism of ActionAntihemophilic factor is a protein found in normal plasma which is necessary for clot formation. The administration of AHF provides an increase in plasma levels of AHF and can temporarily correct the coagulation defect of patients with hemophilia A.
ToxicityN.A.
MetabolismN.A.
AbsorptionN.A.
Volume of DistributionN.A.
Clearance4.1 mL/h/kg [Previously treated pediatric patients]
CategoriesCoagulants and Thrombotic agents
Patents NumberCA1339477
Date of Issue23/09/97
Date of Expiry23/09/14
Drug InteractionN.A.
TargetN.A.
Information of corresponding available drug in the market
Brand NameN.A.
CompanyN.A.
Brand DiscriptionN.A.
Prescribed forN.A.
Chemical NameN.A.
FormulationN.A.
Physcial AppearanceN.A.
Route of AdministrationN.A.
Recommended DosageN.A.
ContraindicationN.A.
Side EffectsSore throat, cough, runny nose; fever or chills; mild nausea, vomiting; unusual or unpleasant taste in your mouth; skin itching or rash.
Useful Linkhttp://www.drugs.com/advate.html
PubMed ID23803235, 23105376, 8328652, 2341766, 4708094, 2831669, 27445511, 25136251, 6197726
3-D StructureTh1022 (View) or (Download)


Entry 3
(3) Primary information
ID1150
ThPP IDTh1022
Therapeutic Peptide/Protein NameAntihemophilic Factor
SequenceATRRYYLGAVELSWDYMQSDLGELPVDARFPPRVPKSFPFNTSVVYKKTL view full sequnce in fasta
Functional ClassificationIa
Molecular Weight264725.5
Chemical FormulaC11794H18314N3220O3553S83
Isoelectric Point6.97
Hydrophobicity-0.533
Melting Point (℃)N.A.
Half Life8.4-19.3 hours
DescriptionHuman recombinant antihemophilic factor or Factor VIII of 2332 residues(glycosylated) is produced by CHO cells.
Indication/DiseaseFor the treatment of hemophilia A, von Willebrand disease and Factor XIII deficiency.
PharmacodynamicsAntihemophilic Factor binds factor IXa along with calcium and phospholipid, this complex converts factor X to factor Xa to facilitate clotting cascade.
Mechanism of ActionAntihemophilic factor is a protein found in normal plasma which is necessary for clot formation. The administration of AHF provides an increase in plasma levels of AHF and can temporarily correct the coagulation defect of patients with hemophilia A.
ToxicityN.A.
MetabolismN.A.
AbsorptionN.A.
Volume of DistributionN.A.
Clearance4.1 mL/h/kg [Previously treated pediatric patients]
CategoriesCoagulants and Thrombotic agents
Patents NumberN.A.
Date of IssueN.A.
Date of ExpiryN.A.
Drug InteractionN.A.
TargetN.A.
Information of corresponding available drug in the market
Brand NameN.A.
CompanyN.A.
Brand DiscriptionN.A.
Prescribed forN.A.
Chemical NameN.A.
FormulationN.A.
Physcial AppearanceN.A.
Route of AdministrationN.A.
Recommended DosageN.A.
ContraindicationN.A.
Side EffectsWarmth, redness, itching, or tingling under your skin; joint pain or swelling; dizziness; headache; or swelling, stinging, or irritation where the injection was given.
Useful Linkhttp://www.baxter.com/healthcare_professionals/products/advate.html
PubMed ID23803235, 23105376, 8328652, 2341766, 4708094, 2831669, 27445511, 25136251, 6197726
3-D StructureTh1022 (View) or (Download)


Entry 4
(4) Primary information
ID1151
ThPP IDTh1022
Therapeutic Peptide/Protein NameAntihemophilic Factor
SequenceATRRYYLGAVELSWDYMQSDLGELPVDARFPPRVPKSFPFNTSVVYKKTL view full sequnce in fasta
Functional ClassificationIa
Molecular Weight264725.5
Chemical FormulaC11794H18314N3220O3553S83
Isoelectric Point6.97
Hydrophobicity-0.533
Melting Point (℃)N.A.
Half Life8.4-19.3 hours
DescriptionHuman recombinant antihemophilic factor or Factor VIII of 2332 residues(glycosylated) is produced by CHO cells.
Indication/DiseaseFor the treatment of hemophilia A, von Willebrand disease and Factor XIII deficiency.
PharmacodynamicsAntihemophilic Factor binds factor IXa along with calcium and phospholipid, this complex converts factor X to factor Xa to facilitate clotting cascade.
Mechanism of ActionAntihemophilic factor is a protein found in normal plasma which is necessary for clot formation. The administration of AHF provides an increase in plasma levels of AHF and can temporarily correct the coagulation defect of patients with hemophilia A.
ToxicityN.A.
MetabolismN.A.
AbsorptionN.A.
Volume of DistributionN.A.
Clearance4.1 mL/h/kg [Previously treated pediatric patients]
CategoriesCoagulants and Thrombotic agents
Patents NumberN.A.
Date of IssueN.A.
Date of ExpiryN.A.
Drug InteractionN.A.
TargetN.A.
Information of corresponding available drug in the market
Brand NameAlphanate
CompanyN.A.
Brand DiscriptionAlphanate(Solvent Detergent / Heat Treated) is a single dose, sterile, lyophilized concentrate of Factor VIII intended for intravenous administration in the treatment of hemophilia A, or acquired Factor VIII deficiency. Alphanate is prepared from pooled h
Prescribed forIt is used for preventing and controlling bleeding in adult patients with hemophilia A. It is also used to control certain types of bleeding episodes (eg, due to injury or surgery) in patients with von Willebrand disease.
Chemical NameN.A.
FormulationWhen reconstituted with the appropriate volume of Sterile Water for Injection, USP, Alphanate contains 0.3 - 0.9 g Albumin (Human)/100 mL; NMT 5 mmol calcium/L; NMT 750 µg glycine/IU FVIIIC; NMT 1.0 U heparin/mL; 10 - 40 mmol histidine/L; NMT 0.1 mg imida
Physcial AppearanceLyophilized powder
Route of AdministrationIntravenous Injection
Recommended DosageBodyweight (in kg) X 0.50 lU/kg X Factor VIII Increase Desired (Percent) = Number of Factor VIII:C IU Required.
ContraindicationContraindicated in patients who have manifested life-threatening immediate hypersensitivity reactions including anaphylaxis to any components of the product.
Side EffectsRash; hives; itching; difficulty breathing; tightness in the chest; swelling of the mouth, face, lips, or tongue); back or stomach pain; calf pain, swelling, or tenderness; chest pain; coughing up blood; dark urine; fever or chills; new or worsening bruis
Useful Linkhttp://www.rxlist.com/alphanate-drug.htm
PubMed ID23803235, 23105376, 8328652, 2341766, 4708094, 2831669, 27445511, 25136251, 6197726
3-D StructureTh1022 (View) or (Download)


Entry 5
(5) Primary information
ID1152
ThPP IDTh1022
Therapeutic Peptide/Protein NameAntihemophilic Factor
SequenceATRRYYLGAVELSWDYMQSDLGELPVDARFPPRVPKSFPFNTSVVYKKTL view full sequnce in fasta
Functional ClassificationIa
Molecular Weight264725.5
Chemical FormulaC11794H18314N3220O3553S83
Isoelectric Point6.97
Hydrophobicity-0.533
Melting Point (℃)N.A.
Half Life8.4-19.3 hours
DescriptionHuman recombinant antihemophilic factor or Factor VIII of 2332 residues(glycosylated) is produced by CHO cells.
Indication/DiseaseFor the treatment of hemophilia A, von Willebrand disease and Factor XIII deficiency.
PharmacodynamicsAntihemophilic Factor binds factor IXa along with calcium and phospholipid, this complex converts factor X to factor Xa to facilitate clotting cascade.
Mechanism of ActionAntihemophilic factor is a protein found in normal plasma which is necessary for clot formation. The administration of AHF provides an increase in plasma levels of AHF and can temporarily correct the coagulation defect of patients with hemophilia A.
ToxicityN.A.
MetabolismN.A.
AbsorptionN.A.
Volume of DistributionN.A.
Clearance4.1 mL/h/kg [Previously treated pediatric patients]
CategoriesCoagulants and Thrombotic agents
Patents NumberN.A.
Date of IssueN.A.
Date of ExpiryN.A.
Drug InteractionN.A.
TargetN.A.
Information of corresponding available drug in the market
Brand NameN.A.
CompanyN.A.
Brand DiscriptionN.A.
Prescribed forN.A.
Chemical NameN.A.
FormulationN.A.
Physcial AppearanceN.A.
Route of AdministrationN.A.
Recommended DosageN.A.
ContraindicationN.A.
Side EffectsN.A.
Useful Linkhttp://www.drugs.com/cdi/alphanate.html
PubMed ID23803235, 23105376, 8328652, 2341766, 4708094, 2831669, 27445511, 25136251, 6197726
3-D StructureTh1022 (View) or (Download)


Entry 6
(6) Primary information
ID1153
ThPP IDTh1022
Therapeutic Peptide/Protein NameAntihemophilic Factor
SequenceATRRYYLGAVELSWDYMQSDLGELPVDARFPPRVPKSFPFNTSVVYKKTL view full sequnce in fasta
Functional ClassificationIa
Molecular Weight264725.5
Chemical FormulaC11794H18314N3220O3553S83
Isoelectric Point6.97
Hydrophobicity-0.533
Melting Point (℃)N.A.
Half Life8.4-19.3 hours
DescriptionHuman recombinant antihemophilic factor or Factor VIII of 2332 residues(glycosylated) is produced by CHO cells.
Indication/DiseaseFor the treatment of hemophilia A, von Willebrand disease and Factor XIII deficiency.
PharmacodynamicsAntihemophilic Factor binds factor IXa along with calcium and phospholipid, this complex converts factor X to factor Xa to facilitate clotting cascade.
Mechanism of ActionAntihemophilic factor is a protein found in normal plasma which is necessary for clot formation. The administration of AHF provides an increase in plasma levels of AHF and can temporarily correct the coagulation defect of patients with hemophilia A.
ToxicityN.A.
MetabolismN.A.
AbsorptionN.A.
Volume of DistributionN.A.
Clearance4.1 mL/h/kg [Previously treated pediatric patients]
CategoriesCoagulants and Thrombotic agents
Patents NumberN.A.
Date of IssueN.A.
Date of ExpiryN.A.
Drug InteractionN.A.
TargetN.A.
Information of corresponding available drug in the market
Brand NameBioclate
CompanyBaxter Healthcare Corporation, Hyland Division and Genetics Institute, Inc.
Brand DiscriptionBioclate is a glycoprotein synthesized by a genetically engineered Chinese Hamster Ovary cell line. In culture the CHO cell line secretes recombinant antihemophilic factor into the cell culture medium. The rAHF is purified from the culture medium utilizin
Prescribed forTo treat or prevent bleeding episodes in adults and children with hemophilia A. It is also used to control bleeding related to surgery or dentistry in a person with hemophilia.
Chemical NameN.A.
FormulationBiocolate is available in single-dose bottles which contain nominally 250, 500 and 1000 International Units per bottle.When reconstituted with the appropriate volume of diluent, it contains the following stabilizers in maximum amounts: 12.5 mg/mL Albumin
Physcial AppearanceSterile, nonpyrogenic, off-white to faint yellow, lyophilized powder
Route of AdministrationIntravenous infusion
Recommended DosageN.A.
ContraindicationAllergic
Side EffectsChest pain; easy bruising, increased bleeding episodes; or bleeding from a wound or where the medicine was injected.
Useful Linkhttp://www.drugs.com/mtm/bioclate-recombinant.html
PubMed ID23803235, 23105376, 8328652, 2341766, 4708094, 2831669, 27445511, 25136251, 6197726
3-D StructureTh1022 (View) or (Download)


Entry 7
(7) Primary information
ID1154
ThPP IDTh1022
Therapeutic Peptide/Protein NameAntihemophilic Factor
SequenceATRRYYLGAVELSWDYMQSDLGELPVDARFPPRVPKSFPFNTSVVYKKTL view full sequnce in fasta
Functional ClassificationIa
Molecular Weight264725.5
Chemical FormulaC11794H18314N3220O3553S83
Isoelectric Point6.97
Hydrophobicity-0.533
Melting Point (℃)N.A.
Half Life8.4-19.3 hours
DescriptionHuman recombinant antihemophilic factor or Factor VIII of 2332 residues(glycosylated) is produced by CHO cells.
Indication/DiseaseFor the treatment of hemophilia A, von Willebrand disease and Factor XIII deficiency.
PharmacodynamicsAntihemophilic Factor binds factor IXa along with calcium and phospholipid, this complex converts factor X to factor Xa to facilitate clotting cascade.
Mechanism of ActionAntihemophilic factor is a protein found in normal plasma which is necessary for clot formation. The administration of AHF provides an increase in plasma levels of AHF and can temporarily correct the coagulation defect of patients with hemophilia A.
ToxicityN.A.
MetabolismN.A.
AbsorptionN.A.
Volume of DistributionN.A.
Clearance4.1 mL/h/kg [Previously treated pediatric patients]
CategoriesCoagulants and Thrombotic agents
Patents NumberN.A.
Date of IssueN.A.
Date of ExpiryN.A.
Drug InteractionN.A.
TargetN.A.
Information of corresponding available drug in the market
Brand NameN.A.
CompanyN.A.
Brand DiscriptionN.A.
Prescribed forN.A.
Chemical NameN.A.
FormulationN.A.
Physcial AppearanceN.A.
Route of AdministrationN.A.
Recommended DosageN.A.
ContraindicationN.A.
Side EffectsSore throat, cough, runny nose; fever or chills; mild nausea, vomiting; unusual or unpleasant taste in your mouth; headache; dizziness; skin itching or rash.
Useful Linkhttp://www.rxlist.com/bioclate-drug.htm
PubMed ID23803235, 23105376, 8328652, 2341766, 4708094, 2831669, 27445511, 25136251, 6197726
3-D StructureTh1022 (View) or (Download)


Entry 8
(8) Primary information
ID1155
ThPP IDTh1022
Therapeutic Peptide/Protein NameAntihemophilic Factor
SequenceATRRYYLGAVELSWDYMQSDLGELPVDARFPPRVPKSFPFNTSVVYKKTL view full sequnce in fasta
Functional ClassificationIa
Molecular Weight264725.5
Chemical FormulaC11794H18314N3220O3553S83
Isoelectric Point6.97
Hydrophobicity-0.533
Melting Point (℃)N.A.
Half Life8.4-19.3 hours
DescriptionHuman recombinant antihemophilic factor or Factor VIII of 2332 residues(glycosylated) is produced by CHO cells.
Indication/DiseaseFor the treatment of hemophilia A, von Willebrand disease and Factor XIII deficiency.
PharmacodynamicsAntihemophilic Factor binds factor IXa along with calcium and phospholipid, this complex converts factor X to factor Xa to facilitate clotting cascade.
Mechanism of ActionAntihemophilic factor is a protein found in normal plasma which is necessary for clot formation. The administration of AHF provides an increase in plasma levels of AHF and can temporarily correct the coagulation defect of patients with hemophilia A.
ToxicityN.A.
MetabolismN.A.
AbsorptionN.A.
Volume of DistributionN.A.
Clearance4.1 mL/h/kg [Previously treated pediatric patients]
CategoriesCoagulants and Thrombotic agents
Patents NumberN.A.
Date of IssueN.A.
Date of ExpiryN.A.
Drug InteractionN.A.
TargetN.A.
Information of corresponding available drug in the market
Brand NameN.A.
CompanyN.A.
Brand DiscriptionN.A.
Prescribed forN.A.
Chemical NameN.A.
FormulationN.A.
Physcial AppearanceN.A.
Route of AdministrationN.A.
Recommended DosageN.A.
ContraindicationN.A.
Side EffectsWarmth, redness, itching, or tingling under your skin; joint pain or swelling; dizziness; headache; or swelling, stinging, or irritation where the injection was given.
Useful Linkhttp://www.webmd.com/drugs/2/drug-18250/bioclate-intravenous/details
PubMed ID23803235, 23105376, 8328652, 2341766, 4708094, 2831669, 27445511, 25136251, 6197726
3-D StructureTh1022 (View) or (Download)


Entry 9
(9) Primary information
ID1156
ThPP IDTh1022
Therapeutic Peptide/Protein NameAntihemophilic Factor
SequenceATRRYYLGAVELSWDYMQSDLGELPVDARFPPRVPKSFPFNTSVVYKKTL view full sequnce in fasta
Functional ClassificationIa
Molecular Weight264725.5
Chemical FormulaC11794H18314N3220O3553S83
Isoelectric Point6.97
Hydrophobicity-0.533
Melting Point (℃)N.A.
Half Life8.4-19.3 hours
DescriptionHuman recombinant antihemophilic factor or Factor VIII of 2332 residues(glycosylated) is produced by CHO cells.
Indication/DiseaseFor the treatment of hemophilia A, von Willebrand disease and Factor XIII deficiency.
PharmacodynamicsAntihemophilic Factor binds factor IXa along with calcium and phospholipid, this complex converts factor X to factor Xa to facilitate clotting cascade.
Mechanism of ActionAntihemophilic factor is a protein found in normal plasma which is necessary for clot formation. The administration of AHF provides an increase in plasma levels of AHF and can temporarily correct the coagulation defect of patients with hemophilia A.
ToxicityN.A.
MetabolismN.A.
AbsorptionN.A.
Volume of DistributionN.A.
Clearance4.1 mL/h/kg [Previously treated pediatric patients]
CategoriesCoagulants and Thrombotic agents
Patents NumberN.A.
Date of IssueN.A.
Date of ExpiryN.A.
Drug InteractionN.A.
TargetN.A.
Information of corresponding available drug in the market
Brand NameHelixate FS
CompanyN.A.
Brand DiscriptionHelixate FS has been manufactured using recombinant DNA technology and is produced by Baby Hamster Kidney cells into which the human factor VIII gene has been introduced. The cell culture medium contains Human Plasma Protein Solution and recombinant insul
Prescribed forTo control and prevent bleeding episodes in adults and children (0-16 years) with hemophilia A and also for surgical prophylaxis in adults and children with hemophilia A. It is also used for routine prophylactic treatment to reduce the frequency of bleedi
Chemical NameN.A.
FormulationHelixate is formulated with sucrose (0.9–1.3%), glycine (21–25 mg/mL), and histidine (18–23 mM) as stabilizers in the final container. The final product also contains calcium chloride (2–3 mM), sodium (27–36 mEq/L), chloride (32–40 mEq/L), polysorbate 80
Physcial AppearanceSterile, stable, purified, nonpyrogenic, dried concentrate
Route of AdministrationIntravenous Injection
Recommended DosageDosage (units) = body weight (kg) _ desired factor VIII rise (IU/dL or % or normal) _ 0.5 (IU/kg per IU/dL)
ContraindicationPatients who have manifested life-threatening immediate hypersensitivity reactions, including anaphylaxis, to the product or its components, including mouse or hamster proteins.
Side EffectsLocal injection site reactions
Useful Linkhttp://www.helixatefs.com/
PubMed ID23803235, 23105376, 8328652, 2341766, 4708094, 2831669, 27445511, 25136251, 6197726
3-D StructureTh1022 (View) or (Download)


Entry 10
(10) Primary information
ID1157
ThPP IDTh1022
Therapeutic Peptide/Protein NameAntihemophilic Factor
SequenceATRRYYLGAVELSWDYMQSDLGELPVDARFPPRVPKSFPFNTSVVYKKTL view full sequnce in fasta
Functional ClassificationIa
Molecular Weight264725.5
Chemical FormulaC11794H18314N3220O3553S83
Isoelectric Point6.97
Hydrophobicity-0.533
Melting Point (℃)N.A.
Half Life8.4-19.3 hours
DescriptionHuman recombinant antihemophilic factor or Factor VIII of 2332 residues(glycosylated) is produced by CHO cells.
Indication/DiseaseFor the treatment of hemophilia A, von Willebrand disease and Factor XIII deficiency.
PharmacodynamicsAntihemophilic Factor binds factor IXa along with calcium and phospholipid, this complex converts factor X to factor Xa to facilitate clotting cascade.
Mechanism of ActionAntihemophilic factor is a protein found in normal plasma which is necessary for clot formation. The administration of AHF provides an increase in plasma levels of AHF and can temporarily correct the coagulation defect of patients with hemophilia A.
ToxicityN.A.
MetabolismN.A.
AbsorptionN.A.
Volume of DistributionN.A.
Clearance4.1 mL/h/kg [Previously treated pediatric patients]
CategoriesCoagulants and Thrombotic agents
Patents NumberN.A.
Date of IssueN.A.
Date of ExpiryN.A.
Drug InteractionN.A.
TargetN.A.
Information of corresponding available drug in the market
Brand NameN.A.
CompanyN.A.
Brand DiscriptionN.A.
Prescribed forN.A.
Chemical NameN.A.
FormulationN.A.
Physcial AppearanceN.A.
Route of AdministrationN.A.
Recommended DosageN.A.
ContraindicationN.A.
Side EffectsDizziness, rash , unusual taste in the mouth , mild increase in blood pressure
Useful Linkhttp://www.drugs.com/pro/helixate-fs.html
PubMed ID23803235, 23105376, 8328652, 2341766, 4708094, 2831669, 27445511, 25136251, 6197726
3-D StructureTh1022 (View) or (Download)


Entry 11
(11) Primary information
ID1158
ThPP IDTh1022
Therapeutic Peptide/Protein NameAntihemophilic Factor
SequenceATRRYYLGAVELSWDYMQSDLGELPVDARFPPRVPKSFPFNTSVVYKKTL view full sequnce in fasta
Functional ClassificationIa
Molecular Weight264725.5
Chemical FormulaC11794H18314N3220O3553S83
Isoelectric Point6.97
Hydrophobicity-0.533
Melting Point (℃)N.A.
Half Life8.4-19.3 hours
DescriptionHuman recombinant antihemophilic factor or Factor VIII of 2332 residues(glycosylated) is produced by CHO cells.
Indication/DiseaseFor the treatment of hemophilia A, von Willebrand disease and Factor XIII deficiency.
PharmacodynamicsAntihemophilic Factor binds factor IXa along with calcium and phospholipid, this complex converts factor X to factor Xa to facilitate clotting cascade.
Mechanism of ActionAntihemophilic factor is a protein found in normal plasma which is necessary for clot formation. The administration of AHF provides an increase in plasma levels of AHF and can temporarily correct the coagulation defect of patients with hemophilia A.
ToxicityN.A.
MetabolismN.A.
AbsorptionN.A.
Volume of DistributionN.A.
Clearance4.1 mL/h/kg [Previously treated pediatric patients]
CategoriesCoagulants and Thrombotic agents
Patents NumberN.A.
Date of IssueN.A.
Date of ExpiryN.A.
Drug InteractionN.A.
TargetN.A.
Information of corresponding available drug in the market
Brand NameN.A.
CompanyN.A.
Brand DiscriptionN.A.
Prescribed forN.A.
Chemical NameN.A.
FormulationN.A.
Physcial AppearanceN.A.
Route of AdministrationN.A.
Recommended DosageN.A.
ContraindicationN.A.
Side EffectsPruritus , depersonalization , nausea , and rhinitis.
Useful Linkhttp://www.rxlist.com/helixate-fs-drug.htm
PubMed ID23803235, 23105376, 8328652, 2341766, 4708094, 2831669, 27445511, 25136251, 6197726
3-D StructureTh1022 (View) or (Download)


Entry 12
(12) Primary information
ID1159
ThPP IDTh1022
Therapeutic Peptide/Protein NameAntihemophilic Factor
SequenceATRRYYLGAVELSWDYMQSDLGELPVDARFPPRVPKSFPFNTSVVYKKTL view full sequnce in fasta
Functional ClassificationIa
Molecular Weight264725.5
Chemical FormulaC11794H18314N3220O3553S83
Isoelectric Point6.97
Hydrophobicity-0.533
Melting Point (℃)N.A.
Half Life8.4-19.3 hours
DescriptionHuman recombinant antihemophilic factor or Factor VIII of 2332 residues(glycosylated) is produced by CHO cells.
Indication/DiseaseFor the treatment of hemophilia A, von Willebrand disease and Factor XIII deficiency.
PharmacodynamicsAntihemophilic Factor binds factor IXa along with calcium and phospholipid, this complex converts factor X to factor Xa to facilitate clotting cascade.
Mechanism of ActionAntihemophilic factor is a protein found in normal plasma which is necessary for clot formation. The administration of AHF provides an increase in plasma levels of AHF and can temporarily correct the coagulation defect of patients with hemophilia A.
ToxicityN.A.
MetabolismN.A.
AbsorptionN.A.
Volume of DistributionN.A.
Clearance4.1 mL/h/kg [Previously treated pediatric patients]
CategoriesCoagulants and Thrombotic agents
Patents NumberN.A.
Date of IssueN.A.
Date of ExpiryN.A.
Drug InteractionN.A.
TargetN.A.
Information of corresponding available drug in the market
Brand NameHemofil M
CompanyN.A.
Brand DiscriptionHemofil M is a human clotting factor derived from pooled human plasma. It works by increasing the amount of clotting factor VII in the blood, helping the blood form clots and stop bleeding
Prescribed forPreventing and controlling bleeding in patients with hemophilia A, including in surgical settings.
Chemical NameN.A.
FormulationHEMOFIL is available as single dose bottles that contain nominally 250 (NDC 0944-2930-01), 500 (NDC 0944-2931-01), 1000 (NDC 0944-2932-01), and 1700 (NDC 0944-2933-01) IU per bottle. Each bottle is labeled with the potency in International Units, and is p
Physcial AppearanceDry concentrate
Route of AdministrationIntravenous Injection
Recommended DosageThe expected in vivo peak AHF level, expressed as IU/dL of plasma or percent of normal, can be calculated by multiplying the dose administered per kg body weight (IU/kg) by two.
ContraindicationAllergic
Side EffectsRash; hives; itching; difficulty breathing; flushing; tightness in the chest; swelling of the mouth, face, lips, or tongue; wheezing; chest pain; fainting; nausea; severe or persistent dizziness or light-headedness; shortness of breath.
Useful Linkhttp://www.drugs.com/cdi/hemofil-m.html
PubMed ID23803235, 23105376, 8328652, 2341766, 4708094, 2831669, 27445511, 25136251, 6197726
3-D StructureTh1022 (View) or (Download)


Entry 13
(13) Primary information
ID1160
ThPP IDTh1022
Therapeutic Peptide/Protein NameAntihemophilic Factor
SequenceATRRYYLGAVELSWDYMQSDLGELPVDARFPPRVPKSFPFNTSVVYKKTL view full sequnce in fasta
Functional ClassificationIa
Molecular Weight264725.5
Chemical FormulaC11794H18314N3220O3553S83
Isoelectric Point6.97
Hydrophobicity-0.533
Melting Point (℃)N.A.
Half Life8.4-19.3 hours
DescriptionHuman recombinant antihemophilic factor or Factor VIII of 2332 residues(glycosylated) is produced by CHO cells.
Indication/DiseaseFor the treatment of hemophilia A, von Willebrand disease and Factor XIII deficiency.
PharmacodynamicsAntihemophilic Factor binds factor IXa along with calcium and phospholipid, this complex converts factor X to factor Xa to facilitate clotting cascade.
Mechanism of ActionAntihemophilic factor is a protein found in normal plasma which is necessary for clot formation. The administration of AHF provides an increase in plasma levels of AHF and can temporarily correct the coagulation defect of patients with hemophilia A.
ToxicityN.A.
MetabolismN.A.
AbsorptionN.A.
Volume of DistributionN.A.
Clearance4.1 mL/h/kg [Previously treated pediatric patients]
CategoriesCoagulants and Thrombotic agents
Patents NumberN.A.
Date of IssueN.A.
Date of ExpiryN.A.
Drug InteractionN.A.
TargetN.A.
Information of corresponding available drug in the market
Brand NameN.A.
CompanyN.A.
Brand DiscriptionN.A.
Prescribed forN.A.
Chemical NameN.A.
FormulationN.A.
Physcial AppearanceN.A.
Route of AdministrationN.A.
Recommended DosageN.A.
ContraindicationN.A.
Side EffectsN.A.
Useful Linkhttp://www.druglib.com/druginfo/hemofil-m/indications_dosage/
PubMed ID23803235, 23105376, 8328652, 2341766, 4708094, 2831669, 27445511, 25136251, 6197726
3-D StructureTh1022 (View) or (Download)


Entry 14
(14) Primary information
ID1161
ThPP IDTh1022
Therapeutic Peptide/Protein NameAntihemophilic Factor
SequenceATRRYYLGAVELSWDYMQSDLGELPVDARFPPRVPKSFPFNTSVVYKKTL view full sequnce in fasta
Functional ClassificationIa
Molecular Weight264725.5
Chemical FormulaC11794H18314N3220O3553S83
Isoelectric Point6.97
Hydrophobicity-0.533
Melting Point (℃)N.A.
Half Life8.4-19.3 hours
DescriptionHuman recombinant antihemophilic factor or Factor VIII of 2332 residues(glycosylated) is produced by CHO cells.
Indication/DiseaseFor the treatment of hemophilia A, von Willebrand disease and Factor XIII deficiency.
PharmacodynamicsAntihemophilic Factor binds factor IXa along with calcium and phospholipid, this complex converts factor X to factor Xa to facilitate clotting cascade.
Mechanism of ActionAntihemophilic factor is a protein found in normal plasma which is necessary for clot formation. The administration of AHF provides an increase in plasma levels of AHF and can temporarily correct the coagulation defect of patients with hemophilia A.
ToxicityN.A.
MetabolismN.A.
AbsorptionN.A.
Volume of DistributionN.A.
Clearance4.1 mL/h/kg [Previously treated pediatric patients]
CategoriesCoagulants and Thrombotic agents
Patents NumberN.A.
Date of IssueN.A.
Date of ExpiryN.A.
Drug InteractionN.A.
TargetN.A.
Information of corresponding available drug in the market
Brand NameHyate:C
CompanyN.A.
Brand DiscriptionN.A.
Prescribed forTo treat and prevent serious bleeding episodes in patients with a bleeding problem called hemophilia A.
Chemical NameN.A.
FormulationN.A.
Physcial AppearancePowder
Route of AdministrationIntravenous Injection
Recommended DosageN.A.
ContraindicationAllergic
Side EffectsFever, changes in facial skin color, chills, fast or irregular breathing, nausea, puffiness or swelling of the eyelids or around the eyes, sensation of burning, warmth, heat, numbness, tightness, or tingling, skin rash, hives, or itching, tightness in the chest, troubled breathing, and unusual tiredness or weakness.
Useful Linkhttp://www.ncbi.nlm.nih.gov/pubmed/2499293
PubMed ID23803235, 23105376, 8328652, 2341766, 4708094, 2831669, 27445511, 25136251, 6197726
3-D StructureTh1022 (View) or (Download)


Entry 15
(15) Primary information
ID1162
ThPP IDTh1022
Therapeutic Peptide/Protein NameAntihemophilic Factor
SequenceATRRYYLGAVELSWDYMQSDLGELPVDARFPPRVPKSFPFNTSVVYKKTL view full sequnce in fasta
Functional ClassificationIa
Molecular Weight264725.5
Chemical FormulaC11794H18314N3220O3553S83
Isoelectric Point6.97
Hydrophobicity-0.533
Melting Point (℃)N.A.
Half Life8.4-19.3 hours
DescriptionHuman recombinant antihemophilic factor or Factor VIII of 2332 residues(glycosylated) is produced by CHO cells.
Indication/DiseaseFor the treatment of hemophilia A, von Willebrand disease and Factor XIII deficiency.
PharmacodynamicsAntihemophilic Factor binds factor IXa along with calcium and phospholipid, this complex converts factor X to factor Xa to facilitate clotting cascade.
Mechanism of ActionAntihemophilic factor is a protein found in normal plasma which is necessary for clot formation. The administration of AHF provides an increase in plasma levels of AHF and can temporarily correct the coagulation defect of patients with hemophilia A.
ToxicityN.A.
MetabolismN.A.
AbsorptionN.A.
Volume of DistributionN.A.
Clearance4.1 mL/h/kg [Previously treated pediatric patients]
CategoriesCoagulants and Thrombotic agents
Patents NumberN.A.
Date of IssueN.A.
Date of ExpiryN.A.
Drug InteractionN.A.
TargetN.A.
Information of corresponding available drug in the market
Brand NameN.A.
CompanyN.A.
Brand DiscriptionN.A.
Prescribed forN.A.
Chemical NameN.A.
FormulationN.A.
Physcial AppearanceN.A.
Route of AdministrationN.A.
Recommended DosageN.A.
ContraindicationN.A.
Side EffectsN.A.
Useful Linkhttp://www.drugs.com/cons/hyate-c.html
PubMed ID23803235, 23105376, 8328652, 2341766, 4708094, 2831669, 27445511, 25136251, 6197726
3-D StructureTh1022 (View) or (Download)


Entry 16
(16) Primary information
ID1163
ThPP IDTh1022
Therapeutic Peptide/Protein NameAntihemophilic Factor
SequenceATRRYYLGAVELSWDYMQSDLGELPVDARFPPRVPKSFPFNTSVVYKKTL view full sequnce in fasta
Functional ClassificationIa
Molecular Weight264725.5
Chemical FormulaC11794H18314N3220O3553S83
Isoelectric Point6.97
Hydrophobicity-0.533
Melting Point (℃)N.A.
Half Life8.4-19.3 hours
DescriptionHuman recombinant antihemophilic factor or Factor VIII of 2332 residues(glycosylated) is produced by CHO cells.
Indication/DiseaseFor the treatment of hemophilia A, von Willebrand disease and Factor XIII deficiency.
PharmacodynamicsAntihemophilic Factor binds factor IXa along with calcium and phospholipid, this complex converts factor X to factor Xa to facilitate clotting cascade.
Mechanism of ActionAntihemophilic factor is a protein found in normal plasma which is necessary for clot formation. The administration of AHF provides an increase in plasma levels of AHF and can temporarily correct the coagulation defect of patients with hemophilia A.
ToxicityN.A.
MetabolismN.A.
AbsorptionN.A.
Volume of DistributionN.A.
Clearance4.1 mL/h/kg [Previously treated pediatric patients]
CategoriesCoagulants and Thrombotic agents
Patents NumberN.A.
Date of IssueN.A.
Date of ExpiryN.A.
Drug InteractionN.A.
TargetN.A.
Information of corresponding available drug in the market
Brand NameN.A.
CompanyN.A.
Brand DiscriptionN.A.
Prescribed forN.A.
Chemical NameN.A.
FormulationN.A.
Physcial AppearanceN.A.
Route of AdministrationN.A.
Recommended DosageN.A.
ContraindicationN.A.
Side EffectsN.A.
Useful Linkhttp://www.webmd.com/drugs/2/drug-75943/hyatec-intravenous/details#interactions
PubMed ID23803235, 23105376, 8328652, 2341766, 4708094, 2831669, 27445511, 25136251, 6197726
3-D StructureTh1022 (View) or (Download)


Entry 17
(17) Primary information
ID1164
ThPP IDTh1022
Therapeutic Peptide/Protein NameAntihemophilic Factor
SequenceATRRYYLGAVELSWDYMQSDLGELPVDARFPPRVPKSFPFNTSVVYKKTL view full sequnce in fasta
Functional ClassificationIa
Molecular Weight264725.5
Chemical FormulaC11794H18314N3220O3553S83
Isoelectric Point6.97
Hydrophobicity-0.533
Melting Point (℃)N.A.
Half Life8.4-19.3 hours
DescriptionHuman recombinant antihemophilic factor or Factor VIII of 2332 residues(glycosylated) is produced by CHO cells.
Indication/DiseaseFor the treatment of hemophilia A, von Willebrand disease and Factor XIII deficiency.
PharmacodynamicsAntihemophilic Factor binds factor IXa along with calcium and phospholipid, this complex converts factor X to factor Xa to facilitate clotting cascade.
Mechanism of ActionAntihemophilic factor is a protein found in normal plasma which is necessary for clot formation. The administration of AHF provides an increase in plasma levels of AHF and can temporarily correct the coagulation defect of patients with hemophilia A.
ToxicityN.A.
MetabolismN.A.
AbsorptionN.A.
Volume of DistributionN.A.
Clearance4.1 mL/h/kg [Previously treated pediatric patients]
CategoriesCoagulants and Thrombotic agents
Patents NumberN.A.
Date of IssueN.A.
Date of ExpiryN.A.
Drug InteractionN.A.
TargetN.A.
Information of corresponding available drug in the market
Brand NameKoate-HP
CompanyN.A.
Brand DiscriptionKoate-HP is a naturally occurring protein in the blood that helps to clot. A lack of antihemophilic factor VIII is the cause of hemophilia A.
Prescribed forTo control and prevent bleeding episodes in people with low levels of factor VIII. It is also used in these patients before surgery to prevent bleeding. People with low factor VIII levels are at risk for bleeding longer after an injury/surgery and for ble
Chemical NameN.A.
FormulationN.A.
Physcial AppearancePowder
Route of AdministrationIntravenous Injection
Recommended DosageN.A.
ContraindicationAllergic
Side EffectsNausea, stomach pain, low fever, loss of appetite, dark urine, clay-colored stools, jaundice (yellowing of the skin or eyes); fever, chills, runny nose, and drowsiness followed about 2 weeks later by a rash and joint pain; fast heart rate, chest pain, troubled breathing and unusual tiredness.
Useful Linkhttp://www.prescriptiondrugs.com/drugs/koate-hp
PubMed ID23803235, 23105376, 8328652, 2341766, 4708094, 2831669, 27445511, 25136251, 6197726
3-D StructureTh1022 (View) or (Download)


Entry 18
(18) Primary information
ID1165
ThPP IDTh1022
Therapeutic Peptide/Protein NameAntihemophilic Factor
SequenceATRRYYLGAVELSWDYMQSDLGELPVDARFPPRVPKSFPFNTSVVYKKTL view full sequnce in fasta
Functional ClassificationIa
Molecular Weight264725.5
Chemical FormulaC11794H18314N3220O3553S83
Isoelectric Point6.97
Hydrophobicity-0.533
Melting Point (℃)N.A.
Half Life8.4-19.3 hours
DescriptionHuman recombinant antihemophilic factor or Factor VIII of 2332 residues(glycosylated) is produced by CHO cells.
Indication/DiseaseFor the treatment of hemophilia A, von Willebrand disease and Factor XIII deficiency.
PharmacodynamicsAntihemophilic Factor binds factor IXa along with calcium and phospholipid, this complex converts factor X to factor Xa to facilitate clotting cascade.
Mechanism of ActionAntihemophilic factor is a protein found in normal plasma which is necessary for clot formation. The administration of AHF provides an increase in plasma levels of AHF and can temporarily correct the coagulation defect of patients with hemophilia A.
ToxicityN.A.
MetabolismN.A.
AbsorptionN.A.
Volume of DistributionN.A.
Clearance4.1 mL/h/kg [Previously treated pediatric patients]
CategoriesCoagulants and Thrombotic agents
Patents NumberN.A.
Date of IssueN.A.
Date of ExpiryN.A.
Drug InteractionN.A.
TargetN.A.
Information of corresponding available drug in the market
Brand NameN.A.
CompanyN.A.
Brand DiscriptionN.A.
Prescribed forN.A.
Chemical NameN.A.
FormulationN.A.
Physcial AppearanceN.A.
Route of AdministrationN.A.
Recommended DosageN.A.
ContraindicationN.A.
Side EffectsUnusual taste in your mouth; cough, runny or stuffy nose; mild itching; swelling in your hands, ankles, or feet; headache or dizziness; mild nausea, diarrhea, stomach pain; sweating; joint pain; or chills or flushing (warmth or tingly feeling).
Useful Linkhttp://www.drugs.com/mtm/koate-hp-injection.html
PubMed ID23803235, 23105376, 8328652, 2341766, 4708094, 2831669, 27445511, 25136251, 6197726
3-D StructureTh1022 (View) or (Download)


Entry 19
(19) Primary information
ID1166
ThPP IDTh1022
Therapeutic Peptide/Protein NameAntihemophilic Factor
SequenceATRRYYLGAVELSWDYMQSDLGELPVDARFPPRVPKSFPFNTSVVYKKTL view full sequnce in fasta
Functional ClassificationIa
Molecular Weight264725.5
Chemical FormulaC11794H18314N3220O3553S83
Isoelectric Point6.97
Hydrophobicity-0.533
Melting Point (℃)N.A.
Half Life8.4-19.3 hours
DescriptionHuman recombinant antihemophilic factor or Factor VIII of 2332 residues(glycosylated) is produced by CHO cells.
Indication/DiseaseFor the treatment of hemophilia A, von Willebrand disease and Factor XIII deficiency.
PharmacodynamicsAntihemophilic Factor binds factor IXa along with calcium and phospholipid, this complex converts factor X to factor Xa to facilitate clotting cascade.
Mechanism of ActionAntihemophilic factor is a protein found in normal plasma which is necessary for clot formation. The administration of AHF provides an increase in plasma levels of AHF and can temporarily correct the coagulation defect of patients with hemophilia A.
ToxicityN.A.
MetabolismN.A.
AbsorptionN.A.
Volume of DistributionN.A.
Clearance4.1 mL/h/kg [Previously treated pediatric patients]
CategoriesCoagulants and Thrombotic agents
Patents NumberN.A.
Date of IssueN.A.
Date of ExpiryN.A.
Drug InteractionN.A.
TargetN.A.
Information of corresponding available drug in the market
Brand NameKogenate FS
CompanyN.A.
Brand DiscriptionKogenate FS is a coagulation factor VIII produced by recombinant DNA technology. It is produced by Baby Hamster Kidney cells into which the human factor VIII gene has been introduced. The cell culture medium contains Human Plasma Protein Solution and reco
Prescribed forKogenate FS is used to treat or prevent bleeding episodes in adults and children with hemophilia A. It is also used to control bleeding related to surgery or dentistry in a person with hemophilia, and to prevent joint damage in people age 16 or older with
Chemical NameN.A.
FormulationKogenate FS is formulated with Sucrose ( 0.9- 1.3%), glycine (210-25mg/ml), histidine (18-23 mmol/L) as stablizers and 27-36mEq/L sodium, 2.0-3.0 mmol/L calcium, 32-40 mEq/L chloride, 64-96 _g/mL polysorbate 80, 28 mg/vial sucrose and trace amounts of Imi
Physcial AppearancePowder
Route of AdministrationIntravenous Injection
Recommended DosageN.A.
ContraindicationAllergic
Side EffectsChest pain; easy bruising, increased bleeding episodes; or bleeding from a wound or where the medicine was injected.
Useful Linkhttp://www.drugs.com/kogenate.html
PubMed ID23803235, 23105376, 8328652, 2341766, 4708094, 2831669, 27445511, 25136251, 6197726
3-D StructureTh1022 (View) or (Download)


Entry 20
(20) Primary information
ID1167
ThPP IDTh1022
Therapeutic Peptide/Protein NameAntihemophilic Factor
SequenceATRRYYLGAVELSWDYMQSDLGELPVDARFPPRVPKSFPFNTSVVYKKTL view full sequnce in fasta
Functional ClassificationIa
Molecular Weight264725.5
Chemical FormulaC11794H18314N3220O3553S83
Isoelectric Point6.97
Hydrophobicity-0.533
Melting Point (℃)N.A.
Half Life8.4-19.3 hours
DescriptionHuman recombinant antihemophilic factor or Factor VIII of 2332 residues(glycosylated) is produced by CHO cells.
Indication/DiseaseFor the treatment of hemophilia A, von Willebrand disease and Factor XIII deficiency.
PharmacodynamicsAntihemophilic Factor binds factor IXa along with calcium and phospholipid, this complex converts factor X to factor Xa to facilitate clotting cascade.
Mechanism of ActionAntihemophilic factor is a protein found in normal plasma which is necessary for clot formation. The administration of AHF provides an increase in plasma levels of AHF and can temporarily correct the coagulation defect of patients with hemophilia A.
ToxicityN.A.
MetabolismN.A.
AbsorptionN.A.
Volume of DistributionN.A.
Clearance4.1 mL/h/kg [Previously treated pediatric patients]
CategoriesCoagulants and Thrombotic agents
Patents NumberN.A.
Date of IssueN.A.
Date of ExpiryN.A.
Drug InteractionN.A.
TargetN.A.
Information of corresponding available drug in the market
Brand NameN.A.
CompanyN.A.
Brand DiscriptionN.A.
Prescribed forN.A.
Chemical NameN.A.
FormulationN.A.
Physcial AppearanceN.A.
Route of AdministrationN.A.
Recommended DosageN.A.
ContraindicationN.A.
Side EffectsSore throat, cough, runny nose; fever or chills; mild nausea, vomiting; unusual or unpleasant taste in your mouth; skin itching or rash; warmth, redness, itching, or tingling under your skin; joint pain or swelling; dizziness; headache; or swelling, stinging, or irritation where the injection was given.
Useful Linkhttp://www.rxlist.com/kogenate-fs-drug.htm
PubMed ID23803235, 23105376, 8328652, 2341766, 4708094, 2831669, 27445511, 25136251, 6197726
3-D StructureTh1022 (View) or (Download)


Entry 21
(21) Primary information
ID1168
ThPP IDTh1022
Therapeutic Peptide/Protein NameAntihemophilic Factor
SequenceATRRYYLGAVELSWDYMQSDLGELPVDARFPPRVPKSFPFNTSVVYKKTL view full sequnce in fasta
Functional ClassificationIa
Molecular Weight264725.5
Chemical FormulaC11794H18314N3220O3553S83
Isoelectric Point6.97
Hydrophobicity-0.533
Melting Point (℃)N.A.
Half Life8.4-19.3 hours
DescriptionHuman recombinant antihemophilic factor or Factor VIII of 2332 residues(glycosylated) is produced by CHO cells.
Indication/DiseaseFor the treatment of hemophilia A, von Willebrand disease and Factor XIII deficiency.
PharmacodynamicsAntihemophilic Factor binds factor IXa along with calcium and phospholipid, this complex converts factor X to factor Xa to facilitate clotting cascade.
Mechanism of ActionAntihemophilic factor is a protein found in normal plasma which is necessary for clot formation. The administration of AHF provides an increase in plasma levels of AHF and can temporarily correct the coagulation defect of patients with hemophilia A.
ToxicityN.A.
MetabolismN.A.
AbsorptionN.A.
Volume of DistributionN.A.
Clearance4.1 mL/h/kg [Previously treated pediatric patients]
CategoriesCoagulants and Thrombotic agents
Patents NumberN.A.
Date of IssueN.A.
Date of ExpiryN.A.
Drug InteractionN.A.
TargetN.A.
Information of corresponding available drug in the market
Brand NameN.A.
CompanyN.A.
Brand DiscriptionN.A.
Prescribed forN.A.
Chemical NameN.A.
FormulationN.A.
Physcial AppearanceN.A.
Route of AdministrationN.A.
Recommended DosageN.A.
ContraindicationN.A.
Side EffectsN.A.
Useful Linkhttp://www.kogenatefs.com/index.php/about-kogenate
PubMed ID23803235, 23105376, 8328652, 2341766, 4708094, 2831669, 27445511, 25136251, 6197726
3-D StructureTh1022 (View) or (Download)


Entry 22
(22) Primary information
ID1169
ThPP IDTh1022
Therapeutic Peptide/Protein NameAntihemophilic Factor
SequenceATRRYYLGAVELSWDYMQSDLGELPVDARFPPRVPKSFPFNTSVVYKKTL view full sequnce in fasta
Functional ClassificationIa
Molecular Weight264725.5
Chemical FormulaC11794H18314N3220O3553S83
Isoelectric Point6.97
Hydrophobicity-0.533
Melting Point (℃)N.A.
Half Life8.4-19.3 hours
DescriptionHuman recombinant antihemophilic factor or Factor VIII of 2332 residues(glycosylated) is produced by CHO cells.
Indication/DiseaseFor the treatment of hemophilia A, von Willebrand disease and Factor XIII deficiency.
PharmacodynamicsAntihemophilic Factor binds factor IXa along with calcium and phospholipid, this complex converts factor X to factor Xa to facilitate clotting cascade.
Mechanism of ActionAntihemophilic factor is a protein found in normal plasma which is necessary for clot formation. The administration of AHF provides an increase in plasma levels of AHF and can temporarily correct the coagulation defect of patients with hemophilia A.
ToxicityN.A.
MetabolismN.A.
AbsorptionN.A.
Volume of DistributionN.A.
Clearance4.1 mL/h/kg [Previously treated pediatric patients]
CategoriesCoagulants and Thrombotic agents
Patents NumberN.A.
Date of IssueN.A.
Date of ExpiryN.A.
Drug InteractionN.A.
TargetN.A.
Information of corresponding available drug in the market
Brand NameMonarc-M
CompanyN.A.
Brand DiscriptionIt is antihyemophilic factor.
Prescribed forTo treat and prevent serious bleeding episodes in patients with hemophilia A.
Chemical NameN.A.
FormulationN.A.
Physcial AppearancePowder
Route of AdministrationIntravenous Injection
Recommended DosageN.A.
ContraindicationAllergic
Side EffectsBlurred vision, flushing, headache, nausea, vomiting
Useful Linkhttp://www.drugs.com/cons/monarc-m.html
PubMed ID23803235, 23105376, 8328652, 2341766, 4708094, 2831669, 27445511, 25136251, 6197726
3-D StructureTh1022 (View) or (Download)


Entry 23
(23) Primary information
ID1170
ThPP IDTh1022
Therapeutic Peptide/Protein NameAntihemophilic Factor
SequenceATRRYYLGAVELSWDYMQSDLGELPVDARFPPRVPKSFPFNTSVVYKKTL view full sequnce in fasta
Functional ClassificationIa
Molecular Weight264725.5
Chemical FormulaC11794H18314N3220O3553S83
Isoelectric Point6.97
Hydrophobicity-0.533
Melting Point (℃)N.A.
Half Life8.4-19.3 hours
DescriptionHuman recombinant antihemophilic factor or Factor VIII of 2332 residues(glycosylated) is produced by CHO cells.
Indication/DiseaseFor the treatment of hemophilia A, von Willebrand disease and Factor XIII deficiency.
PharmacodynamicsAntihemophilic Factor binds factor IXa along with calcium and phospholipid, this complex converts factor X to factor Xa to facilitate clotting cascade.
Mechanism of ActionAntihemophilic factor is a protein found in normal plasma which is necessary for clot formation. The administration of AHF provides an increase in plasma levels of AHF and can temporarily correct the coagulation defect of patients with hemophilia A.
ToxicityN.A.
MetabolismN.A.
AbsorptionN.A.
Volume of DistributionN.A.
Clearance4.1 mL/h/kg [Previously treated pediatric patients]
CategoriesCoagulants and Thrombotic agents
Patents NumberN.A.
Date of IssueN.A.
Date of ExpiryN.A.
Drug InteractionN.A.
TargetN.A.
Information of corresponding available drug in the market
Brand NameN.A.
CompanyN.A.
Brand DiscriptionN.A.
Prescribed forN.A.
Chemical NameN.A.
FormulationN.A.
Physcial AppearanceN.A.
Route of AdministrationN.A.
Recommended DosageN.A.
ContraindicationN.A.
Side EffectsAllergic reactions like skin rash, itching or hives, swelling of the face, lips, or tongue, chest pain, fast, irregular heartbeat, feeling faint or lightheaded, falls, fever or chills, flu-like symptoms, numbness or tingling in hands or feet, pain, redness or swelling at the injection site, stomach pain, unusually weak or tired and yellowing of the eyes or skin.
Useful Linkhttp://www.cvs.com/drug/monarc-m
PubMed ID23803235, 23105376, 8328652, 2341766, 4708094, 2831669, 27445511, 25136251, 6197726
3-D StructureTh1022 (View) or (Download)


Entry 24
(24) Primary information
ID1171
ThPP IDTh1022
Therapeutic Peptide/Protein NameAntihemophilic Factor
SequenceATRRYYLGAVELSWDYMQSDLGELPVDARFPPRVPKSFPFNTSVVYKKTL view full sequnce in fasta
Functional ClassificationIa
Molecular Weight264725.5
Chemical FormulaC11794H18314N3220O3553S83
Isoelectric Point6.97
Hydrophobicity-0.533
Melting Point (℃)N.A.
Half Life8.4-19.3 hours
DescriptionHuman recombinant antihemophilic factor or Factor VIII of 2332 residues(glycosylated) is produced by CHO cells.
Indication/DiseaseFor the treatment of hemophilia A, von Willebrand disease and Factor XIII deficiency.
PharmacodynamicsAntihemophilic Factor binds factor IXa along with calcium and phospholipid, this complex converts factor X to factor Xa to facilitate clotting cascade.
Mechanism of ActionAntihemophilic factor is a protein found in normal plasma which is necessary for clot formation. The administration of AHF provides an increase in plasma levels of AHF and can temporarily correct the coagulation defect of patients with hemophilia A.
ToxicityN.A.
MetabolismN.A.
AbsorptionN.A.
Volume of DistributionN.A.
Clearance4.1 mL/h/kg [Previously treated pediatric patients]
CategoriesCoagulants and Thrombotic agents
Patents NumberN.A.
Date of IssueN.A.
Date of ExpiryN.A.
Drug InteractionN.A.
TargetN.A.
Information of corresponding available drug in the market
Brand NameMonoclate-P
CompanyN.A.
Brand DiscriptionMonoclate-P, Factor VIII:C Pasteurized, Monoclonal Antibody Purified, is a sterile, stable, lyophilized concentrate of Factor VIII:C with reduced amounts of VWF:Ag and purified of extraneous plasma-derived protein by use of affinity chromatography. A muri
Prescribed forTo control and prevent bleeding episodes in people with hemophilia A. It is also used in these patients before surgery to prevent bleeding.
Chemical NameN.A.
FormulationEach vial contains the labeled amount of antihemophilic factor (AHF) activity as expressed in terms of International Units (I.U.) of antihemophilic activity. One unit of antihemophilic activity is equivalent to that quantity of AHF present in one mL of no
Physcial AppearanceLyophilized powder for solution
Route of AdministrationIntravenous Injection
Recommended DosageThe following formula provides a guide of dosage calculations for both adult and pediatric patients:Number of AHF I.U. Required = Body weight(in kg) x desired Factor VIII increase(% normal) x 0.5
ContraindicationHypersensitivity to mouse protein
Side EffectsProducts of this type are known to cause allergic reactions, mild chills, nausea or stinging at the infusion site. In some cases, inhibitors of FVIII may occur.
Useful Linkhttp://www.abopharmaceuticals.com/ProductSheets/MonoclateP.pdf
PubMed ID23803235, 23105376, 8328652, 2341766, 4708094, 2831669, 27445511, 25136251, 6197726
3-D StructureTh1022 (View) or (Download)


Entry 25
(25) Primary information
ID1172
ThPP IDTh1022
Therapeutic Peptide/Protein NameAntihemophilic Factor
SequenceATRRYYLGAVELSWDYMQSDLGELPVDARFPPRVPKSFPFNTSVVYKKTL view full sequnce in fasta
Functional ClassificationIa
Molecular Weight264725.5
Chemical FormulaC11794H18314N3220O3553S83
Isoelectric Point6.97
Hydrophobicity-0.533
Melting Point (℃)N.A.
Half Life8.4-19.3 hours
DescriptionHuman recombinant antihemophilic factor or Factor VIII of 2332 residues(glycosylated) is produced by CHO cells.
Indication/DiseaseFor the treatment of hemophilia A, von Willebrand disease and Factor XIII deficiency.
PharmacodynamicsAntihemophilic Factor binds factor IXa along with calcium and phospholipid, this complex converts factor X to factor Xa to facilitate clotting cascade.
Mechanism of ActionAntihemophilic factor is a protein found in normal plasma which is necessary for clot formation. The administration of AHF provides an increase in plasma levels of AHF and can temporarily correct the coagulation defect of patients with hemophilia A.
ToxicityN.A.
MetabolismN.A.
AbsorptionN.A.
Volume of DistributionN.A.
Clearance4.1 mL/h/kg [Previously treated pediatric patients]
CategoriesCoagulants and Thrombotic agents
Patents NumberN.A.
Date of IssueN.A.
Date of ExpiryN.A.
Drug InteractionN.A.
TargetN.A.
Information of corresponding available drug in the market
Brand NameN.A.
CompanyN.A.
Brand DiscriptionN.A.
Prescribed forN.A.
Chemical NameN.A.
FormulationN.A.
Physcial AppearanceN.A.
Route of AdministrationN.A.
Recommended DosageN.A.
ContraindicationN.A.
Side EffectsN.A.
Useful Linkhttp://www.drugs.com/pro/monoclate-p.html
PubMed ID23803235, 23105376, 8328652, 2341766, 4708094, 2831669, 27445511, 25136251, 6197726
3-D StructureTh1022 (View) or (Download)


Entry 26
(26) Primary information
ID1173
ThPP IDTh1022
Therapeutic Peptide/Protein NameAntihemophilic Factor
SequenceATRRYYLGAVELSWDYMQSDLGELPVDARFPPRVPKSFPFNTSVVYKKTL view full sequnce in fasta
Functional ClassificationIa
Molecular Weight264725.5
Chemical FormulaC11794H18314N3220O3553S83
Isoelectric Point6.97
Hydrophobicity-0.533
Melting Point (℃)N.A.
Half Life8.4-19.3 hours
DescriptionHuman recombinant antihemophilic factor or Factor VIII of 2332 residues(glycosylated) is produced by CHO cells.
Indication/DiseaseFor the treatment of hemophilia A, von Willebrand disease and Factor XIII deficiency.
PharmacodynamicsAntihemophilic Factor binds factor IXa along with calcium and phospholipid, this complex converts factor X to factor Xa to facilitate clotting cascade.
Mechanism of ActionAntihemophilic factor is a protein found in normal plasma which is necessary for clot formation. The administration of AHF provides an increase in plasma levels of AHF and can temporarily correct the coagulation defect of patients with hemophilia A.
ToxicityN.A.
MetabolismN.A.
AbsorptionN.A.
Volume of DistributionN.A.
Clearance4.1 mL/h/kg [Previously treated pediatric patients]
CategoriesCoagulants and Thrombotic agents
Patents NumberN.A.
Date of IssueN.A.
Date of ExpiryN.A.
Drug InteractionN.A.
TargetN.A.
Information of corresponding available drug in the market
Brand NameN.A.
CompanyN.A.
Brand DiscriptionN.A.
Prescribed forN.A.
Chemical NameN.A.
FormulationN.A.
Physcial AppearanceN.A.
Route of AdministrationN.A.
Recommended DosageN.A.
ContraindicationN.A.
Side EffectsN.A.
Useful Linkhttp://www.rxlist.com/monoclate-p-drug.htm
PubMed ID23803235, 23105376, 8328652, 2341766, 4708094, 2831669, 27445511, 25136251, 6197726
3-D StructureTh1022 (View) or (Download)


Entry 27
(27) Primary information
ID1174
ThPP IDTh1022
Therapeutic Peptide/Protein NameAntihemophilic Factor
SequenceATRRYYLGAVELSWDYMQSDLGELPVDARFPPRVPKSFPFNTSVVYKKTL view full sequnce in fasta
Functional ClassificationIa
Molecular Weight264725.5
Chemical FormulaC11794H18314N3220O3553S83
Isoelectric Point6.97
Hydrophobicity-0.533
Melting Point (℃)N.A.
Half Life8.4-19.3 hours
DescriptionHuman recombinant antihemophilic factor or Factor VIII of 2332 residues(glycosylated) is produced by CHO cells.
Indication/DiseaseFor the treatment of hemophilia A, von Willebrand disease and Factor XIII deficiency.
PharmacodynamicsAntihemophilic Factor binds factor IXa along with calcium and phospholipid, this complex converts factor X to factor Xa to facilitate clotting cascade.
Mechanism of ActionAntihemophilic factor is a protein found in normal plasma which is necessary for clot formation. The administration of AHF provides an increase in plasma levels of AHF and can temporarily correct the coagulation defect of patients with hemophilia A.
ToxicityN.A.
MetabolismN.A.
AbsorptionN.A.
Volume of DistributionN.A.
Clearance4.1 mL/h/kg [Previously treated pediatric patients]
CategoriesCoagulants and Thrombotic agents
Patents NumberN.A.
Date of IssueN.A.
Date of ExpiryN.A.
Drug InteractionN.A.
TargetN.A.
Information of corresponding available drug in the market
Brand NameReFacto
CompanyN.A.
Brand DiscriptionReFacto Antihemophilic Factor (Recombinant) is a purified protein produced by recombinant DNA technology for use in therapy of factor VIII deficiency. ReFacto (antihemophilic factor) is a glycoprotein with an approximate molecular mass of 170 kDa consisti
Prescribed forTo control and prevent hemorrhagic episodes and for surgical prophylaxis in patients with hemophilia A. ReFacto is indicated for short-term routine prophylaxis to reduce the frequency of spontaneous bleeding episodes
Chemical NameN.A.
FormulationIt is available in single-use vials containing the labeled amount of factor VIII activity. Each vial contains nominally 250, 500, 1000 or 2000 IU of ReFacto (antihemophilic factor) per vial. The formulated product is a clear colorless solution upon recons
Physcial AppearanceLyophilized powder
Route of AdministrationIntravenous Injection
Recommended DosageRequired units = body weight (kg)x desired factor VIII rise (IU/dL or % of normal)x 0.5 (IU/kg per IU/dL)
ContraindicationKnown hypersensitivity to mouse or hamster proteins
Side EffectsChest pain; easy bruising, increased bleeding episodes; or bleeding from a wound or where the medicine was injected.
Useful Linkhttp://www.drugs.com/mtm/refacto-recombinant.html
PubMed ID23803235, 23105376, 8328652, 2341766, 4708094, 2831669, 27445511, 25136251, 6197726
3-D StructureTh1022 (View) or (Download)


Entry 28
(28) Primary information
ID1175
ThPP IDTh1022
Therapeutic Peptide/Protein NameAntihemophilic Factor
SequenceATRRYYLGAVELSWDYMQSDLGELPVDARFPPRVPKSFPFNTSVVYKKTL view full sequnce in fasta
Functional ClassificationIa
Molecular Weight264725.5
Chemical FormulaC11794H18314N3220O3553S83
Isoelectric Point6.97
Hydrophobicity-0.533
Melting Point (℃)N.A.
Half Life8.4-19.3 hours
DescriptionHuman recombinant antihemophilic factor or Factor VIII of 2332 residues(glycosylated) is produced by CHO cells.
Indication/DiseaseFor the treatment of hemophilia A, von Willebrand disease and Factor XIII deficiency.
PharmacodynamicsAntihemophilic Factor binds factor IXa along with calcium and phospholipid, this complex converts factor X to factor Xa to facilitate clotting cascade.
Mechanism of ActionAntihemophilic factor is a protein found in normal plasma which is necessary for clot formation. The administration of AHF provides an increase in plasma levels of AHF and can temporarily correct the coagulation defect of patients with hemophilia A.
ToxicityN.A.
MetabolismN.A.
AbsorptionN.A.
Volume of DistributionN.A.
Clearance4.1 mL/h/kg [Previously treated pediatric patients]
CategoriesCoagulants and Thrombotic agents
Patents NumberN.A.
Date of IssueN.A.
Date of ExpiryN.A.
Drug InteractionN.A.
TargetN.A.
Information of corresponding available drug in the market
Brand NameN.A.
CompanyN.A.
Brand DiscriptionN.A.
Prescribed forN.A.
Chemical NameN.A.
FormulationN.A.
Physcial AppearanceN.A.
Route of AdministrationN.A.
Recommended DosageN.A.
ContraindicationN.A.
Side EffectsSore throat, cough, runny nose; fever or chills; mild nausea, vomiting; unusual or unpleasant taste in your mouth; skin itching or rash; warmth, redness, itching, or tingling under your skin; joint pain or swelling; dizziness; headache; or swelling, stinging, or irritation where the injection was given.
Useful Linkhttp://www.medicines.org.uk/emc/medicine/21767/SPC
PubMed ID23803235, 23105376, 8328652, 2341766, 4708094, 2831669, 27445511, 25136251, 6197726
3-D StructureTh1022 (View) or (Download)


Entry 29
(29) Primary information
ID1176
ThPP IDTh1022
Therapeutic Peptide/Protein NameAntihemophilic Factor
SequenceATRRYYLGAVELSWDYMQSDLGELPVDARFPPRVPKSFPFNTSVVYKKTL view full sequnce in fasta
Functional ClassificationIa
Molecular Weight264725.5
Chemical FormulaC11794H18314N3220O3553S83
Isoelectric Point6.97
Hydrophobicity-0.533
Melting Point (℃)N.A.
Half Life8.4-19.3 hours
DescriptionHuman recombinant antihemophilic factor or Factor VIII of 2332 residues(glycosylated) is produced by CHO cells.
Indication/DiseaseFor the treatment of hemophilia A, von Willebrand disease and Factor XIII deficiency.
PharmacodynamicsAntihemophilic Factor binds factor IXa along with calcium and phospholipid, this complex converts factor X to factor Xa to facilitate clotting cascade.
Mechanism of ActionAntihemophilic factor is a protein found in normal plasma which is necessary for clot formation. The administration of AHF provides an increase in plasma levels of AHF and can temporarily correct the coagulation defect of patients with hemophilia A.
ToxicityN.A.
MetabolismN.A.
AbsorptionN.A.
Volume of DistributionN.A.
Clearance4.1 mL/h/kg [Previously treated pediatric patients]
CategoriesCoagulants and Thrombotic agents
Patents NumberN.A.
Date of IssueN.A.
Date of ExpiryN.A.
Drug InteractionN.A.
TargetN.A.
Information of corresponding available drug in the market
Brand NameN.A.
CompanyN.A.
Brand DiscriptionN.A.
Prescribed forN.A.
Chemical NameN.A.
FormulationN.A.
Physcial AppearanceN.A.
Route of AdministrationN.A.
Recommended DosageN.A.
ContraindicationN.A.
Side EffectsN.A.
Useful Linkhttp://www.rxlist.com/refacto-drug.htm
PubMed ID23803235, 23105376, 8328652, 2341766, 4708094, 2831669, 27445511, 25136251, 6197726
3-D StructureTh1022 (View) or (Download)


Entry 30
(30) Primary information
ID1177
ThPP IDTh1022
Therapeutic Peptide/Protein NameAntihemophilic Factor
SequenceATRRYYLGAVELSWDYMQSDLGELPVDARFPPRVPKSFPFNTSVVYKKTL view full sequnce in fasta
Functional ClassificationIa
Molecular Weight264725.5
Chemical FormulaC11794H18314N3220O3553S83
Isoelectric Point6.97
Hydrophobicity-0.533
Melting Point (℃)N.A.
Half Life8.4-19.3 hours
DescriptionHuman recombinant antihemophilic factor or Factor VIII of 2332 residues(glycosylated) is produced by CHO cells.
Indication/DiseaseFor the treatment of hemophilia A, von Willebrand disease and Factor XIII deficiency.
PharmacodynamicsAntihemophilic Factor binds factor IXa along with calcium and phospholipid, this complex converts factor X to factor Xa to facilitate clotting cascade.
Mechanism of ActionAntihemophilic factor is a protein found in normal plasma which is necessary for clot formation. The administration of AHF provides an increase in plasma levels of AHF and can temporarily correct the coagulation defect of patients with hemophilia A.
ToxicityN.A.
MetabolismN.A.
AbsorptionN.A.
Volume of DistributionN.A.
Clearance4.1 mL/h/kg [Previously treated pediatric patients]
CategoriesCoagulants and Thrombotic agents
Patents NumberN.A.
Date of IssueN.A.
Date of ExpiryN.A.
Drug InteractionN.A.
TargetN.A.
Information of corresponding available drug in the market
Brand NameXyntha
CompanyN.A.
Brand DiscriptionAntihemophilic Factor (Recombinant), Plasma/Albumin-Free, the active ingredient in XYNTHA, is a recombinant coagulation factor VIII produced by recombinant DNA technology for use in therapy of factor VIII deficiency. The Antihemophilic Factor (Recombinant
Prescribed forXyntha is used to treat or prevent bleeding episodes in adults and children with hemophilia A. It is also used to control bleeding related to surgery or dentistry in a person with hemophilia A.
Chemical NameN.A.
FormulationEach single-use vial contains nominally 250, 500, 1000 or 2000 IU of XYNTHA (antihemophilic factor) . Upon reconstitution, the product is a clear to slightly opalescent, colorless solution that contains sodium chloride, sucrose, L-histidine, calcium chlor
Physcial AppearanceSterile, nonpyrogenic, preservative-free, freeze-dried powder
Route of AdministrationIntravenous Injection
Recommended DosageRequired units = body weight (kg) x desired factor VIII rise (IU/dL or % of normal) x 0.5 (IU/kg per IU/dL)
ContraindicationN.A.
Side EffectsChest pain; easy bruising, increased bleeding episodes; or bleeding from a wound or where the medicine was injected.
Useful Linkhttp://www.xyntha.com/
PubMed ID23803235, 23105376, 8328652, 2341766, 4708094, 2831669, 27445511, 25136251, 6197726
3-D StructureTh1022 (View) or (Download)


Entry 31
(31) Primary information
ID1178
ThPP IDTh1022
Therapeutic Peptide/Protein NameAntihemophilic Factor
SequenceATRRYYLGAVELSWDYMQSDLGELPVDARFPPRVPKSFPFNTSVVYKKTL view full sequnce in fasta
Functional ClassificationIa
Molecular Weight264725.5
Chemical FormulaC11794H18314N3220O3553S83
Isoelectric Point6.97
Hydrophobicity-0.533
Melting Point (℃)N.A.
Half Life8.4-19.3 hours
DescriptionHuman recombinant antihemophilic factor or Factor VIII of 2332 residues(glycosylated) is produced by CHO cells.
Indication/DiseaseFor the treatment of hemophilia A, von Willebrand disease and Factor XIII deficiency.
PharmacodynamicsAntihemophilic Factor binds factor IXa along with calcium and phospholipid, this complex converts factor X to factor Xa to facilitate clotting cascade.
Mechanism of ActionAntihemophilic factor is a protein found in normal plasma which is necessary for clot formation. The administration of AHF provides an increase in plasma levels of AHF and can temporarily correct the coagulation defect of patients with hemophilia A.
ToxicityN.A.
MetabolismN.A.
AbsorptionN.A.
Volume of DistributionN.A.
Clearance4.1 mL/h/kg [Previously treated pediatric patients]
CategoriesCoagulants and Thrombotic agents
Patents NumberN.A.
Date of IssueN.A.
Date of ExpiryN.A.
Drug InteractionN.A.
TargetN.A.
Information of corresponding available drug in the market
Brand NameN.A.
CompanyN.A.
Brand DiscriptionN.A.
Prescribed forN.A.
Chemical NameN.A.
FormulationN.A.
Physcial AppearanceN.A.
Route of AdministrationN.A.
Recommended DosageN.A.
ContraindicationN.A.
Side EffectsSore throat, cough, runny nose; fever or chills; mild nausea, vomiting; unusual or unpleasant taste in your mouth; skin itching or rash; warmth, redness, itching, or tingling under your skin; joint pain or swelling; dizziness; headache; or swelling, stinging, or irritation where the injection was given.
Useful Linkhttp://www.drugs.com/xyntha.html
PubMed ID23803235, 23105376, 8328652, 2341766, 4708094, 2831669, 27445511, 25136251, 6197726
3-D StructureTh1022 (View) or (Download)


Entry 32
(32) Primary information
ID1179
ThPP IDTh1022
Therapeutic Peptide/Protein NameAntihemophilic Factor
SequenceATRRYYLGAVELSWDYMQSDLGELPVDARFPPRVPKSFPFNTSVVYKKTL view full sequnce in fasta
Functional ClassificationIa
Molecular Weight264725.5
Chemical FormulaC11794H18314N3220O3553S83
Isoelectric Point6.97
Hydrophobicity-0.533
Melting Point (℃)N.A.
Half Life8.4-19.3 hours
DescriptionHuman recombinant antihemophilic factor or Factor VIII of 2332 residues(glycosylated) is produced by CHO cells.
Indication/DiseaseFor the treatment of hemophilia A, von Willebrand disease and Factor XIII deficiency.
PharmacodynamicsAntihemophilic Factor binds factor IXa along with calcium and phospholipid, this complex converts factor X to factor Xa to facilitate clotting cascade.
Mechanism of ActionAntihemophilic factor is a protein found in normal plasma which is necessary for clot formation. The administration of AHF provides an increase in plasma levels of AHF and can temporarily correct the coagulation defect of patients with hemophilia A.
ToxicityN.A.
MetabolismN.A.
AbsorptionN.A.
Volume of DistributionN.A.
Clearance4.1 mL/h/kg [Previously treated pediatric patients]
CategoriesCoagulants and Thrombotic agents
Patents NumberN.A.
Date of IssueN.A.
Date of ExpiryN.A.
Drug InteractionN.A.
TargetN.A.
Information of corresponding available drug in the market
Brand NameN.A.
CompanyN.A.
Brand DiscriptionN.A.
Prescribed forN.A.
Chemical NameN.A.
FormulationN.A.
Physcial AppearanceN.A.
Route of AdministrationN.A.
Recommended DosageN.A.
ContraindicationN.A.
Side EffectsN.A.
Useful Linkhttp://www.rxlist.com/xyntha-drug.htm
PubMed ID23803235, 23105376, 8328652, 2341766, 4708094, 2831669, 27445511, 25136251, 6197726
3-D StructureTh1022 (View) or (Download)